Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
07 2022
Historique:
received: 16 06 2021
revised: 28 09 2021
accepted: 12 10 2021
pubmed: 8 4 2022
medline: 29 6 2022
entrez: 7 4 2022
Statut: ppublish

Résumé

The incidence of invasive disease caused by group A streptococcus (GAS) has increased in multiple countries in the past 15 years. However, despite these reports, to the best of our knowledge, no systematic reviews and combined estimates of the incidence of invasive GAS have been done in key high-risk groups. To address this, we estimated the incidence of invasive GAS disease, including death and disability outcomes, among two high-risk groups-namely, pregnant women and children younger than 5 years. We did a systematic review and meta-analyses on invasive GAS outcomes, including incidence, case fatality risks, and neurodevelopmental impairment risk, among pregnant women, neonates (younger than 28 days), infants (younger than 1 year), and children (younger than 5 years) worldwide and by income region. We searched several databases for articles published from Jan 1, 2000, to June 3, 2020, for publications that reported invasive GAS outcomes, and we sought unpublished data from an investigator group of collaborators. We included studies with data on invasive GAS cases, defined as laboratory isolation of Streptococcus pyogenes from any normally sterile site, or isolation of S pyogenes from a non-sterile site in a patient with necrotising fasciitis or streptococcal toxic shock syndrome. For inclusion in pooled incidence estimates, studies had to report a population denominator, and for inclusion in pooled estimates of case fatality risk, studies had to report aggregate data on the outcome of interest and the total number of cases included as a denominator. We excluded studies focusing on groups at very high risk (eg, only preterm infants). We assessed heterogeneity with I Of the 950 published articles and 29 unpublished datasets identified, 20 studies (seven unpublished; 3829 cases of invasive GAS) from 12 countries provided sufficient data to be included in pooled estimates of outcomes. We did not identify studies reporting invasive GAS incidence among pregnant women in low-income and middle-income countries (LMICs) nor any reporting neurodevelopmental impairment after invasive GAS in LMICs. In nine studies from high-income countries (HICs) that reported invasive GAS in pregnancy and the post-partum period, invasive GAS incidence was 0·12 per 1000 livebirths (95% CI 0·11 to 0·14; I We found a substantial burden of invasive GAS among young children. In LMICs, little data were available for neonates and children and no data were available for pregnant women. Incidences of invasive GAS are likely to be underestimates, particularly in LMICs, due to low GAS surveillance. It is essential to improve available data to inform development of prevention and management strategies for invasive GAS. Wellcome Trust.

Sections du résumé

BACKGROUND
The incidence of invasive disease caused by group A streptococcus (GAS) has increased in multiple countries in the past 15 years. However, despite these reports, to the best of our knowledge, no systematic reviews and combined estimates of the incidence of invasive GAS have been done in key high-risk groups. To address this, we estimated the incidence of invasive GAS disease, including death and disability outcomes, among two high-risk groups-namely, pregnant women and children younger than 5 years.
METHODS
We did a systematic review and meta-analyses on invasive GAS outcomes, including incidence, case fatality risks, and neurodevelopmental impairment risk, among pregnant women, neonates (younger than 28 days), infants (younger than 1 year), and children (younger than 5 years) worldwide and by income region. We searched several databases for articles published from Jan 1, 2000, to June 3, 2020, for publications that reported invasive GAS outcomes, and we sought unpublished data from an investigator group of collaborators. We included studies with data on invasive GAS cases, defined as laboratory isolation of Streptococcus pyogenes from any normally sterile site, or isolation of S pyogenes from a non-sterile site in a patient with necrotising fasciitis or streptococcal toxic shock syndrome. For inclusion in pooled incidence estimates, studies had to report a population denominator, and for inclusion in pooled estimates of case fatality risk, studies had to report aggregate data on the outcome of interest and the total number of cases included as a denominator. We excluded studies focusing on groups at very high risk (eg, only preterm infants). We assessed heterogeneity with I
FINDINGS
Of the 950 published articles and 29 unpublished datasets identified, 20 studies (seven unpublished; 3829 cases of invasive GAS) from 12 countries provided sufficient data to be included in pooled estimates of outcomes. We did not identify studies reporting invasive GAS incidence among pregnant women in low-income and middle-income countries (LMICs) nor any reporting neurodevelopmental impairment after invasive GAS in LMICs. In nine studies from high-income countries (HICs) that reported invasive GAS in pregnancy and the post-partum period, invasive GAS incidence was 0·12 per 1000 livebirths (95% CI 0·11 to 0·14; I
INTERPRETATION
We found a substantial burden of invasive GAS among young children. In LMICs, little data were available for neonates and children and no data were available for pregnant women. Incidences of invasive GAS are likely to be underestimates, particularly in LMICs, due to low GAS surveillance. It is essential to improve available data to inform development of prevention and management strategies for invasive GAS.
FUNDING
Wellcome Trust.

Identifiants

pubmed: 35390294
pii: S1473-3099(21)00672-1
doi: 10.1016/S1473-3099(21)00672-1
pmc: PMC9217756
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076-1088

Subventions

Organisme : Wellcome Trust
ID : 205184/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205184
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Crown Copyright © 2022 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Pediatr Res. 2013 Dec;74 Suppl 1:73-85
pubmed: 24366464
Clin Infect Dis. 2019 Aug 16;69(5):877-883
pubmed: 30624673
J Pediatric Infect Dis Soc. 2019 Mar 28;8(1):46-52
pubmed: 29309631
Epidemiol Infect. 2011 Apr;139(4):623-8
pubmed: 20609283
J Clin Microbiol. 2008 Jan;46(1):79-86
pubmed: 17959766
J Pediatr. 2016 Jul;174:218-225.e4
pubmed: 27117198
J Clin Microbiol. 2005 Apr;43(4):1678-83
pubmed: 15814984
Epidemiol Infect. 2008 May;136(5):621-7
pubmed: 17631691
Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
Clin Microbiol Infect. 2019 Feb;25(2):251.e1-251.e4
pubmed: 30336220
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Clin Microbiol. 2008 Jul;46(7):2359-67
pubmed: 18463210
J Infect Dis. 2009 Sep 15;200(6):906-15
pubmed: 19671016
Euro Surveill. 2011 Oct 13;16(41):
pubmed: 22008200
Obstet Gynecol. 2014 Apr;123(4):874-82
pubmed: 24785617
BMC Pediatr. 2015 Apr 02;15:33
pubmed: 25884449
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Paediatr Int Child Health. 2015 Aug;35(3):252-64
pubmed: 26052891
Clin Infect Dis. 2007 Aug 15;45(4):450-8
pubmed: 17638193
BJOG. 2015 Apr;122(5):663-71
pubmed: 24862293
J Infect. 2015 Feb;70(2):127-34
pubmed: 25246363
BJOG. 2019 Jan;126(1):44-53
pubmed: 30070056
Lancet Respir Med. 2018 Mar;6(3):223-230
pubmed: 29508706
J Infect Dis. 1978 Sep;138(3):287-92
pubmed: 359723
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S89-S99
pubmed: 29117323
BMC Public Health. 2019 Dec 30;19(1):1750
pubmed: 31888568
Emerg Infect Dis. 2009 Feb;15(2):216-22
pubmed: 19193265
Lancet Glob Health. 2014 Dec;2(12):e717-26
pubmed: 25433627
Vaccine. 2018 Jun 7;36(24):3397-3405
pubmed: 29496349
Clin Infect Dis. 2017 Nov 06;65(suppl_2):S190-S199
pubmed: 29117331
Clin Infect Dis. 2021 Dec 6;73(11):e3718-e3726
pubmed: 32803254
J Clin Microbiol. 2016 Jan;54(1):83-92
pubmed: 26491184
J Clin Microbiol. 2016 Jan;54(1):134-41
pubmed: 26560536
Emerg Infect Dis. 2016 Feb;22(2):224-32
pubmed: 26811918
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Emerg Infect Dis. 2005 Jan;11(1):77-82
pubmed: 15705326
Commun Dis Intell (2018). 2019 Mar 15;43:
pubmed: 30879286
Lancet Glob Health. 2016 Oct;4(10):e752-60
pubmed: 27633433
Clin Infect Dis. 2017 Nov 06;65(suppl_2):S160-S172
pubmed: 29117326
Med J Aust. 2007 Jun 4;186(11):565-9
pubmed: 17547544
Infect Dis Obstet Gynecol. 2015;2015:518562
pubmed: 26494975
Trop Med Int Health. 2015 Jan;20(1):40-7
pubmed: 25354844
Lancet. 2012 Feb 4;379(9814):445-52
pubmed: 22244654
JAMA. 1982 May 21;247(19):2680-2
pubmed: 7043001
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
Drugs. 2012 Jun 18;72(9):1213-27
pubmed: 22686614
Emerg Infect Dis. 2011 Jun;17(6):983-9
pubmed: 21749758
Obstet Gynecol. 2016 Feb;127(2):227-32
pubmed: 26942347
Clin Microbiol Infect. 2015 Feb;21(2):171-8
pubmed: 25658557
J Child Neurol. 2016 May;31(6):683-90
pubmed: 26500243
Clin Infect Dis. 2012 Aug;55(4):479-87
pubmed: 22534148
Clin Infect Dis. 2005 Aug 1;41(3):334-42
pubmed: 16007530
Clin Infect Dis. 2014 Oct;59(7):e84-92
pubmed: 24965347
Indian J Med Res. 2011 Jan;133:110-5
pubmed: 21321428
FEMS Immunol Med Microbiol. 2010 Apr;58(3):389-96
pubmed: 20146737
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
Med Mal Infect. 2015 Nov-Dec;45(11-12):470-4
pubmed: 26602794
Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):2131-6
pubmed: 26292935

Auteurs

Emma Sherwood (E)

Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: emmasherwood@nhs.net.

Stefania Vergnano (S)

Paediatric Infectious Diseases, Bristol Royal Hospital for Children, University Hospitals Bristol NHS, Bristol, UK.

Isona Kakuchi (I)

Paediatric Infectious Diseases, Bristol Royal Hospital for Children, University Hospitals Bristol NHS, Bristol, UK.

Michael G Bruce (MG)

Centers for Disease Control and Prevention, Arctic Investigations Program, Anchorage, Alaska, USA.

Suman Chaurasia (S)

Department of Paediatrics, All India Institute of Medical Sciences, New Delhi, India.

Samara David (S)

British Columbia Centre for Disease Control, University of British Columbia, BC, Canada.

Angela Dramowski (A)

Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Scarlett Georges (S)

Infectious Diseases Department, Santé Publique France, French National Public Health Agency, St Maurice, France.

Rebecca Guy (R)

National Infection Service, UK Health Security Agency, London, UK.

Theresa Lamagni (T)

National Infection Service, UK Health Security Agency, London, UK.

Daniel Levy-Bruhl (D)

Infectious Diseases Department, Santé Publique France, French National Public Health Agency, St Maurice, France.

Outi Lyytikäinen (O)

National Institute for Health and Welfare, Department of Health Security, Infectious Disease Control and Vaccinations Unit, Helsinki, Finland.

Monika Naus (M)

British Columbia Centre for Disease Control, University of British Columbia, BC, Canada.

Jennifer Onukwube Okaro (JO)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Oddvar Oppegaard (O)

Department of Medicine, Haukeland University Hospital, Bergen, Norway.

Didrik F Vestrheim (DF)

Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway.

Tammy Zulz (T)

Centers for Disease Control and Prevention, Arctic Investigations Program, Anchorage, Alaska, USA.

Andrew C Steer (AC)

Murdoch Children's Research Institute, Melbourne, VIC, Australia.

Chris A Van Beneden (CA)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Anna C Seale (AC)

Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH